MedTrace Logo

Letrozole in Patients With Hepatopulmonary Syndrome

NCT04577001 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-05-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety, tolerability and possible benefit of letrozole compared to placebo in patients with Hepatopulmonary Syndrome.

Conditions

  • Hepatopulmonary Syndrome

Interventions

DRUG

Letrozole

2.5 mg orally daily for 6 months

DRUG

Placebo

No active ingredient taken orally daily for 6 months

Sponsors & Collaborators

Principal Investigators

  • Hilary M DuBrock, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2021-03-26
Completion
2021-03-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577001 on ClinicalTrials.gov